Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case ...

Regeneron Pharmaceuticals Inc. closed 44.49% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Regeneron Pharmaceuticals Inc. closed 45.10% below its 52-week high of $1,211.20, which the company reached on August 27th.

We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

Melody Heeju Hong, a senior at General Douglas MacArthur High School in Levittown, has placed sixth in the prestigious 2025 ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

The teen is the first student from Levittown's General Douglas MacArthur High School to be named a finalist in the ...

EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...

The Dermatology Foundation (DF) and the Skin of Color Society (SOCS) announce that Crystal U. Aguh, MD, FAAD, is the 2025 ...